FDA Approves Cymbalta(R) For Treatment Of Generalized Anxiety Disorder
Tue, 27 Feb 2007 08:00 AM EST
... Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta(R) (duloxetine HCl) for the treatment of generalized anxiety disorder (GAD), a condition that affects more than 6.5 million American adults in a given year. [click link for full article] ...
Related Topics
- Generalized Anxiety Disorder
- Duloxetine
- Anxiety
- Social Phobia
- Adrenal Gland Disorders
- Panic Disorder
- Obsessive Compulsive Disorder
- Sleep Disorders
- Dissociative Disorders
- Bipolar Disorder
- Genetic Disorders
- Borderline Personality Disorder
- Personality Disorders
- Seizure Disorder
- Language Disorders
- Seasonal Affective Disorder
- Post Traumatic Stress Disorder
- Blood Disorders
- Voice Disorders
- Anxiety disorder

Not Signed In -

